Big pharma has been accused of having had its day, but Motley Fool Share Advisor senior analyst David Kuo tells TMF managing director Jill Ralph that he can see the light at the end of the tunnel. In this edition, David puts GlaxoSmithKlineAstraZeneca(LSE:AZN)Shire(LSE:SHP), and Hikma(LSE:HIK) through their paces, and explains why he's bullish on each of them.

Investing is by no means easy in today's uncertain economy. That's why we've published "Top Sectors for 2012" -- our guide to three favorable industries. This free report will be dispatched immediately to your inbox.

Further Motley Fool investment opportunities:

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.